Newsroom

Sorted by: Latest
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Clean Edge Global Water UCITS ETF 18.08.2026 H2O LN IE000Q8F0M81  600,002.00 USD  12,200,188.61   20.334  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 18.08.2026 SDVI.LN IE000YVOQ2A3   40,361.00 USD   1,208,991.42   29.954  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 18.08.2026 FKUD IE00BD9N0445  121,463.00 GBP   3,787,041.36   31.179  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust RBA American Industrial Renaissance UCITS ETF 18.08.2026 AIRR LN IE000U6ABUJ7 7,900,002.00 USD 230,914,933.72   29.230  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 18.08.2026 FGBL.LN IE00BYTH6121  781,889.00 USD  81,125,978.90  103.756  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF 10% - January 18.08.2026 FJAN.LN IE000MDKBOB3  150,002.00 USD   4,405,334.32   29.369  ...
-

Caleres to Announce Second Quarter 2026 Results on September 10

ST. LOUIS--(BUSINESS WIRE)--Caleres (NYSE: CAL), a market-leading portfolio of consumer-driven footwear brands, will release its second quarter 2026 financial results before market open on Thursday, September 10, 2026. Following the announcement, company executives will host a conference call at 10 a.m. Eastern Time to discuss results and provide a general business update. Investors, Caleres associates, media, and the public are invited to join the call. Participants in North America can dial (...
-

Movado Group, Inc. Announces Date of Conference Call and Webcast for Second Quarter Fiscal Year 2027 Results

PARAMUS, N.J.--(BUSINESS WIRE)--Movado Group, Inc. (NYSE: MOV) invites investors to listen to a live broadcast of the Company's conference call to discuss second quarter fiscal year 2027 earnings results on Wednesday, August 26, 2026, at 9:00 a.m. Eastern Time. A press release detailing the Company’s second quarter fiscal year 2027 results will be issued before the market opens and prior to the call. The conference call will be hosted by Efraim Grinberg, Chairman and Chief Executive Officer, an...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 18.08.2026 GINC LN IE00BD842Y21  858,787.00 USD  58,268,340.35   67.850  ...
-

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck’s a...